Clinical trials: Infection and Inflammatory Reaction
Bacterial Infections
Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment
Inadequate treatment of infections frequently leads to complications that cause new visits to the doctor, lengthen hospital stays and can lead to sepsis, even causing the death of affected patients.
- Trial name
- EVIAST (NCT06174519)
- Testing
- Medical device simulation
- Where
- Spain
- Volunteers
- 325 people
- Sponsor
- Pragmatech AI Solutions
Embolism and Thrombosis, Cardiovascular
Collection of Blood Samples for New Diagnostic Devices 2
To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor…
- Conditions
- Embolism and Thrombosis, Cardiovascular, Renal, Inflammation
- Trial name
- NOVEL-2 (NCT05568966)
- Testing
- Venous blood draw, Fingerstick
- Where
- 7 sites in United Kingdom
- Volunteers
- 20,000 people
- Sponsor
- LumiraDx UK Limited
Sepsis, Septic Shock
Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
One of the significants health problems in the world is sepsis, with the number of cases reaching 20-30 million per year, according to the WHO.
- Trial name
- NCT06602245
- Where
- 4 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Efferon JSC
Chronic Hepatitis C
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or…
- Trial name
- JKB122 (NCT02293941)
- Testing
- JKB-122 5mg, JKB-122 15mg, JKB-122 35mg
- Where
- 14 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Onychomycosis
Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis
The purpose of the study is to evaluate and compare the efficacy of the sequential association RV4104A ointment followed by ciclopiroxolamine 1% cream and ciclopirox 8% film-forming solution versus amorolfine 5% nail lacquer…
- Trial name
- ONICO (NCT01014637)
- Testing
- Amorolfine (Antifungal), RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
- Where
- 7 sites in France
- Volunteers
- 260 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Intraocular Inflammation, Suspected Endophthalmitis
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Specific study objectives include: To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually).
- Trial name
- NCT05791695
- Testing
- Non Applicable
- Where
- United States
- Volunteers
- 155,413 people
- Sponsor
- Regeneron Pharmaceuticals
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)
The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of…
- Trial name
- direcT2 (NCT01752166)
- Where
- 8 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- T2 Biosystems
Sepsis, Bacteriemia
Safety and Efficacy of Immages System in Patients Recieving IV Therapy
The study will evaluate the functionality of IMMAGES , an intravenous infusion device system, in patients hospitalized in Bait Balev hospital.
- Conditions
- Sepsis, Bacteriemia, CHF
- Trial name
- IV (NCT02020811)
- Testing
- Sentinel
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- PRo-IV
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Hepatitis B Infection, Congenital Malformation
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
Immunoprophylaxis with two hepatitis B vaccinations following the hepatitis B immune globulin (HBIg) and hepatitis B vaccine at birth is largely effective in protecting infants from hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia
- Trial name
- NCT03476083
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
- Where
- 7 sites in China
- Volunteers
- 280 people
- Sponsor
- New Discovery LLC
Toxic-Shock Syndrome, Sepsis
Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02971670
- Testing
- rTSST-1 Variant Candidate Vaccine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Sepsis Associated Disseminated Intravascular Coagulation (DIC)
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
This study is designed to evaluate a new investigational drug, BAY 3389934, in healthy Japanese volunteers. The primary purpose is to see how safe the drug is and how well it is tolerated by the body when given at different…
- Trial name
- NCT07176728
- Testing
- BAY 3389934
- Where
- 2 sites in Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Otitis Externa, Otorhinolaryngologic Diseases
Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis
The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro (0.3% Ciprofloxacin Otic Foam), used once-daily for 7 days for the treatment of Acute Diffuse Otitis Externa, compared to commercial ear drops used…
- Conditions
- Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases, Otitis
- Trial name
- Once-a-day (NCT01157819)
- Testing
- 0.3% Ciprofloxacin Ear Drops, FoamOtic Cipro
- Where
- 2 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Otic Pharma
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411899
- Testing
- Sonelokimab
- Where
- 109 sites in United States, Bulgaria and 8 more
- Volunteers
- 422 people
- Sponsor
- MoonLake Immunotherapeutics AG
Severe Sepsis
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
- Trial name
- NCT00630656
- Testing
- Talactoferrin alfa
- Where
- 34 sites in United States, Canada and 3 more
- Volunteers
- 190 people
- Sponsor
- Agennix
Acute Pancreatitis With Uninfected Necrosis, Unspecified
Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF).
- Trial name
- NCT05695001
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 34 people
- Sponsor
- Efferon JSC
Sepsis
Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial
This study will analyze HostDx Sepsis results from whole blood samples collected from patients with suspected sepsis or at risk for sepsis in the surgical ICU
- Trial name
- NCT04414189
- Testing
- HostDx Sepsis
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Inflammatix
Skin Infection, Abscess
Complicated Skin and Skin Structure Infections
The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
- Conditions
- Skin Infection, Abscess, Cellulitis
- Trial name
- NCT00619710
- Testing
- Meropenem, Imipenem-cilastatin
- Volunteers
- 1,000 people
- Sponsor
- Pfizer
Sepsis
SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis
This Phase IIa Randomized, Double-blind, Parallel Group, Placebo-controlled, multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Intravenous Injection of SY-005（recombinant human annexin…
- Trial name
- NCT04898322
- Testing
- SY-005
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data